Flexion in-licenses four compounds

Flexion Therapeutics Inc. (Woburn, Mass.) in-licensed four compounds from three pharma companies. Flexion received one compound each from AstraZeneca plc (LSE:AZN; NYSE:AZN) and Merck Serono S.A., and two compounds from an undisclosed company. This year, Flexion plans to begin Phase I or Phase II trials of the compounds, which include FX002 for autoimmune diseases, FX003 for ulcerative colitis, FX004 for tinnitus and FX005 for intra-articular treatment of osteoarthritis. The three companies are eligible for undisclosed milestones and royalties. Merck Serono is a division of Merck KGaA (Xetra:MRK). ...